Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Proteins with expanded polyglutamine repeats cause Huntington's disease and other neurodegenerative diseases. Transcriptional dysregulation and loss of function of transcriptional co-activator proteins have been implicated in the pathogenesis of these diseases. Huntington's disease is caused by expansion of a repeated sequence of the amino acid glutamine in the abnormal protein huntingtin (Htt). Here we show that the polyglutamine-containing domain of Htt, Htt exon 1 protein (Httex1p), directly binds the acetyltransferase domains of two distinct proteins: CREB-binding protein (CBP) and p300/CBP-associated factor (P/CAF). In cell-free assays, Httex1p also inhibits the acetyltransferase activity of at least three enzymes: p300, P/CAF and CBP. Expression of Httex1p in cultured cells reduces the level of the acetylated histones H3 and H4, and this reduction can be reversed by administering inhibitors of histone deacetylase (HDAC). In vivo, HDAC inhibitors arrest ongoing progressive neuronal degeneration induced by polyglutamine repeat expansion, and they reduce lethality in two Drosophila models of polyglutamine disease. These findings raise the possibility that therapy with HDAC inhibitors may slow or prevent the progressive neurodegeneration seen in Huntington's disease and other polyglutamine-repeat diseases, even after the onset of symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The progression of neurodegeneration is slowed by treatment with deacetylase inhibitors, further emphasizing the impor- tance of a controlled balance of protein acetylation and deacetylation in cellular functions in diverse tissues (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
In the citing paper
“A recent report showed that neurodegeneration triggered by expression of the polyglutamine-containing protein Httex1p involves inhibition of CBP/p300- and PCAF-AT activities (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
Citations
Cites
Targeted gene expression as a means of altering cell fates and generating dominant phenotypes
Brand, A. H., & Perrimon, N. (1993) · Development · doi:10.1242/dev.118.2.401 · Cited by 9,612
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595 · cited 1×
“We found that even normal repeat Htt can bind to and inhibit acetyltransferase activity ( Figs 1 and 2 ), so why is pathology associated with only expanded repeat Htt? Mutant Htt can be proteolytically processed; the pathogenic fragment localizes to the nucleus, where it is capable of inhibiting acetyltransferase acti…”
BackgroundA p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479 · cited 1×
“, pGST–P/CAF-AT domain (encoding amino acids 87–768), and pcDNA3 containing the cDNA for P/CA”
MethodGlutamine Repeats and Neurodegeneration
Zoghbi, H. Y., & Orr, H. T. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.217 · Cited by 1,309 · cited 1×
“The aetiology of several other neurodegenerative diseases, including spinocerebellar ataxia I and Kennedy's disease, also involves expansion of a polyglutamine repea”
BackgroundHistone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Nucifora, F. C., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V. L., et al. (2001) · Science · doi:10.1126/science.1056784 · Cited by 1,094
Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,062 · cited 1×
“We previously found that a fragment of mutant Htt interacts directly with CBP, which contains an acetyltransferase domain and is a co-activator of numerous promoter”
BackgroundSelf-citationLuo, L., Liao, Y. J., Jan, L. Y., & Jan, Y. N. (1994) · Genes & Development · doi:10.1101/gad.8.15.1787 · Cited by 983
Cited by
Items 201–300 of 1,000
McConoughey, S. J., Basso, M., Niatsetskaya, Z. V., Sleiman, S. F., Smirnova, N. A., Langley, B. C., Mahishi, L., Cooper, A. J. L., Antonyak, M. A., Cerione, R. A., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000084 · Cited by 146
Self-citationBiological and Potential Therapeutic Roles of Sirtuin Deacetylases
Taylor, D. M., Maxwell, M. M., Luthi‐Carter, R., & Kazantsev, A. G. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8357-y · Cited by 162
Self-citationPolyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle
Riley, B. E., & Orr, H. T. (2006) · Genes & Development · doi:10.1101/gad.1436506 · Cited by 169
“…huntingtin and CBP interact via their polyglutamine stretches, that huntingtin with an expanded polyglutamine tract interferes with CBP-activated gene expression, and that overexpression of CBP rescued polyglutamine-induced toxicity in cultured cells (Nucifora et al. 2001; Steffan et al. 2001).”
InfluentialRole of histone and transcription factor acetylation in diabetes pathogenesis
Gray, S. G., & De Meyts, P. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.559 · Cited by 144
Wu, J., Shih, H.-P., Vigont, V. A., Hrdlicka, L., Diggins, L. T., Singh, C. M., Mahoney, M. B., Chesworth, R., Shapiro, G., Zimina, O. A., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.04.012 · Cited by 145
“NF-kB activation has been observed in PC12 cells transfected with mutant Huntingtin construct, in R6/2 transgenic HD mice and in HD knock-in mice (Khoshnan et al., 2004; Sugars et al., 2004).”
Bates, E. A., Victor, M., Jones, A. K., Shi, Y., & Hart, A. C. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3344-05.2006 · Cited by 144
“…the expanded polyglutamine form of huntingtin protein binds the acetyltransferase cAMP response element-binding protein (CREB) binding protein (CBP); both huntingtin and CBP are sequestered into aggregates (McCampbell et al., 2000; Nucifora et al., 2001; Steffan et al., 2001; Jiang et al., 2003).”
BackgroundJia, H., Kast, R. J., Steffan, J. S., & Thomas, E. A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds379 · Cited by 143
Self-citationMechanisms of Disease: histone modifications in Huntington's disease
Sadri‐Vakili, G., & Cha, J.-H. J. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0199 · Cited by 162
Mechanisms of protein toxicity in neurodegenerative diseases
Chung, C. G., Lee, H., & Lee, S. B. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2854-4 · Cited by 142
“Consistently, a previous study reported that the mutant htt and ataxin-3 proteins could directly bind to histone acetyltransferases, such as CBP and p300/CBP-associated factor (P/CAF), thereby impairing histone acetylation in neurons [32, 33].”
BackgroundAltered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor
Lieberman, A. P. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.17.1967 · Cited by 143
Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies
Wolfgang, W. J., Miller, T. W., Webster, J. M., Huston, J. S., Thompson, L. M., Marsh, J. L., & Messer, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505321102 · Cited by 141
Self-citationTaylor, J. P., Taye, A. A., Campbell, C., Kazemi-Esfarjani, P., Fischbeck, K. H., & Min, K.-T. (2003) · Genes & Development · doi:10.1101/gad.1087503 · Cited by 142
“Physical interaction between CBP and mutant protein has been found to depend on the acetyltransferase domain of the former and the polyglutamine tract of the latter (Steffan et al. 2001).”
BackgroundLu, X.-H., Mattis, V. B., Wang, N., Al-Ramahi, I., van den Berg, N., Fratantoni, S. A., Waldvogel, H., Greiner, E., Osmand, A., Elzein, K., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010523 · Cited by 137
Polyglutamine fibrillogenesis: The pathway unfolds
Ross, C. A., Poirier, M. A., Wanker, E. E., & Amzel, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237018100 · Cited by 138
Epigenetic Mechanisms and Gene Networks in the Nervous System
Colvis, C. M., Pollock, J. D., Goodman, R. H., Impey, S., Dunn, J., Mandel, G., Champagne, F. A., Mayford, M., Korzus, E., Kumar, A., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4119-05.2005 · Cited by 138
Decreased cAMP Response Element-mediated Transcription
Sugars, K. L., Brown, R., J. Cook, L., Swartz, J., & Rubinsztein, D. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310226200 · Cited by 137
Glutathione peroxidase activity is neuroprotective in models of Huntington's disease
Mason, R. P., Casu, M., Butler, N., Breda, C., Campesan, S., Clapp, J., Green, E. W., Dhulkhed, D., Kyriacou, C. P., & Giorgini, F. (2013) · Nature Genetics · doi:10.1038/ng.2732 · Cited by 136
Tsai, C.-C., Kao, H.-Y., Mitzutani, A., Banayo, E., Rajan, H., McKeown, M., & Evans, R. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400615101 · Cited by 137
Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin
Jiang, H., Poirier, M. A., Liang, Y., Pei, Z., Weiskittel, C. E., Smith, W. W., DeFranco, D. B., & Ross, C. A. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.011 · Cited by 137
“This region is similar to the region of CBP (amino acids 1459 to 1877) that most strongly interacts with mutant htt in vitro (Steffan et al., 2001).”
InfluentialDawson, T. M., Mandir, A. S., & Lee, M. K. (2002) · Neuron · doi:10.1016/s0896-6273(02)00780-8 · Cited by 154
Chan, E. Y. W. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.17.1939 · Cited by 137
Draper, I., Kurshan, P. T., McBride, E. W., Jackson, F. R., & Kopin, A. S. (2007) · Developmental Neurobiology · doi:10.1002/dneu.20355 · Cited by 157
“Indeed, flies are amenable to pharmacologic manipulations which may com- plement results obtained from genetic alterations (Min and Benzer, 1999; Steffan et al., 2001; Rival et al., 2004).”
BackgroundCardiac dysfunction in the R6/2 mouse model of Huntington’s disease
Mihm, M. J., Amann, D. M., Schanbacher, B. L., Altschuld, R. A., Bauer, J. A., & Hoyt, K. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.016 · Cited by 149
Bito, H., & Takemoto-Kimura, S. (2003) · Cell Calcium · doi:10.1016/s0143-4160(03)00140-4 · Cited by 135
A cell-based screen for drugs to treat Huntington's disease
Aiken, C. T., Tobin, A. J., & Schweitzer, E. S. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.04.001 · Cited by 135
HDAC4 inhibits cell‐cycle progression and protects neurons from cell death
Majdzadeh, N., Wang, L., Morrison, B. E., Bassel‐Duby, R., Olson, E. N., & D'Mello, S. R. (2008) · Developmental Neurobiology · doi:10.1002/dneu.20637 · Cited by 134
“elegans, Drosophila, and mouse models of polyglutamine toxicity (Steffan et al., 2001; Ferrante et al., 2003; Hockly et al., 2003; Jeong et al., 2003; Ryu et al., 2003; Kanai et al., 2004; Gardian et al., 2005; Bates et al., 2006; Chen et al., 2006).”
Satterfield, T. F., Jackson, S. M., & Pallanck, L. J. (2002) · Genetics · doi:10.1093/genetics/162.4.1687 · Cited by 135
CREB-Binding Protein Modulates Repeat Instability in a Drosophila Model for PolyQ Disease
Jung, J., & Bonini, N. (2007) · Science · doi:10.1126/science.1139517 · Cited by 133
Protein aggregation in motor neurone disorders
Wood, J. D., Beaujeux, T. P., & Shaw, P. J. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.0305-1846.2003.00518.x · Cited by 133
Song, C., Kanthasamy, A., Jin, H., Anantharam, V., & Kanthasamy, A. G. (2011) · NeuroToxicology · doi:10.1016/j.neuro.2011.05.018 · Cited by 129
“…result in the accumulation of hyperacetylated histones, followed by the transcriptional activation of certain genes by weakening histone–DNA interactions, relaxing the DNA conformation, and regulating the cell cycle and apoptosis (Butler and Bates, 2006; Langley et al., 2005; Steffan et al., 2001).”
BackgroundInfluentialWilburn, B., Rudnicki, D. D., Zhao, J., Weitz, T. M., Cheng, Y., Gu, X., Greiner, E., Park, C. S., Wang, N., Sopher, B. L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.03.021 · Cited by 129
“To test this hypothesis, we used two different wild-type JPH3 BAC transgenic control mice.”
MethodRouaux, C., Loeffler, J., & Boutillier, A. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.035 · Cited by 149
Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice
Smith, K. M., Matson, S., Matson, W. R., Cormier, K., Del Signore, S. J., Hagerty, S. W., Stack, E. C., Ryu, H., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.004 · Cited by 127
“In contrast, there are classes of agents, such as transglutaminase inhibitors (cystamine) and histone deacetylase inhibitors (butyrates) where the results of efficacy in outcome measures are agreed upon across laboratories [16–20,41–43].”
BackgroundValor, L. M., Pulopulos, M. M., Jimenez-Minchan, M., Olivares, R., Lutz, B., & Barco, A. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4737-10.2011 · Cited by 127
“Independent studies have shown that the administration of HDACis attenuates neuronal loss in animal models for HD (Steffan et al., 2001; Ferrante et al., 2003; Hockly et al., 2003), AD (Fischer et al., 2007), and other neurodegenerative diseases (Minamiyama et al., 2004; Mai et al., 2009).”
BackgroundPathophysiology of Huntingtonʼs disease: from huntingtin functions to potential treatments
Roze, E., Saudou, F., & Caboche, J. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328304b692 · Cited by 127
Hathorn, T., Snyder-Keller, A., & Messer, A. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.08.017 · Cited by 123
HDAC inhibitors and neurodegeneration: At the edge between protection and damage
Dietz, K. C., & Casaccia, P. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.011 · Cited by 126
“This expanded polyglutamine sequence can interact with and disrupt the normal distribution of the histone acetyltransferase CREB-binding protein (CBP) [40-45] and interfere with CBP-targeted transcription [46].”
BackgroundMethodInfluentialMitochondrial dynamics, a key executioner in neurodegenerative diseases
Panchal, K., & Tiwari, A. K. (2018) · Mitochondrion · doi:10.1016/j.mito.2018.11.002 · Cited by 136
SUMO-2 and PIAS1 Modulate Insoluble Mutant Huntingtin Protein Accumulation
O’Rourke, J. G., Gareau, J. R., Ochaba, J., Song, W., Raskó, T., Reverter, D., Lee, J., Monteys, A. M., Pallos, J., Mee, L., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.06.034 · Cited by 125
“…in Mutant HTTex1p-Expressing Drosophila To validate the potential involvement of PIAS proteins in HD pathogenesis in vivo, the single Drosophila PIAS protein, Su(-var)2-10 (dPIAS) (Hari et al., 2001), was evaluated for its effect on HD-like phenotypes in a fly model (Steffan et al., 2001).”
MethodSelf-citationModeling Neurodegenerative Disorders in Drosophila melanogaster
Bolus, H., Crocker, K. L., Boekhoff‐Falk, G., & Chtarbanova, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093055 · Cited by 148
Drosophila models of neurodegenerative disease
Sang, T., & Jackson, G. R. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.438 · Cited by 153
Self-citationChemical regulation of epigenetic modifications: Opportunities for new cancer therapy
Zheng, Y. G., Wu, J., Chen, Z., & Goodman, M. (2008) · Medicinal Research Reviews · doi:10.1002/med.20120 · Cited by 123
“It has been reported that polyglutamine repeats inhibit HATactivity to manifest the mutant phenotype, which can be ameliorated with HDAC inhibitor treatment.(195) Such a polyglutamine motif may be useful to design synthetic ligand for HAT inhibition.”
Andreassen, O. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0562 · Cited by 123
Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy
McLendon, P. M., Ferguson, B. S., Osinska, H., Bhuiyan, M. S., James, J., McKinsey, T. A., & Robbins, J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415589111 · Cited by 120
Transcellular spreading of huntingtin aggregates in the Drosophila brain
Babcock, D. T., & Ganetzky, B. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516217112 · Cited by 120
Curcumin modulates cell death and is protective in Huntington’s disease model
Chongtham, A., & Agrawal, N. (2016) · Scientific Reports · doi:10.1038/srep18736 · Cited by 137
Kozikowski, A. P., Chen, Y., Gaysin, A., Chen, B., D'Annibale, M. A., Suto, C. M., & Langley, B. C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070178x · Cited by 118
Altered transcription in yeast expressing expanded polyglutamine
Hughes, R. E., Lo, R. S., Davis, C. P., Strand, A. D., Neal, C. L., Olson, J. M., & Fields, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191498198 · Cited by 137
Stress-induced epigenetic transcriptional memory of acetylcholinesterase by HDAC4
Sailaja, B. S., Cohen-Carmon, D., Zimmerman, G., Soreq, H., & Meshorer, E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209990110 · Cited by 121
The promise and perils of HDAC inhibitors in neurodegeneration
Didonna, A., & Opal, P. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.147 · Cited by 118
Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA)
Katsuno, M., Tanaka, F., Adachi, H., Banno, H., Suzuki, K., Watanabe, H., & Sobue, G. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.05.007 · Cited by 134
“Alternatively, the interaction between transcriptional co-activators and soluble polyglutamine-expanded proteins has also been demonstrated in animal models of polyglutamine diseases as well as in postmortem tissues of patients (Steffan et al., 2001).”
Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice
Yu, Z.-X. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.8.905 · Cited by 121
Kanai, H., Sawa, A., Chen, R.-W., Leeds, P. R., & Chuang, D. M. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500269 · Cited by 124
Redundant Control of Adipogenesis by Histone Deacetylases 1 and 2
Haberland, M., Carrer, M., Mokalled, M. H., Montgomery, R. L., & Olson, E. N. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081679 · Cited by 118
Histone Deacetylases and Mood Disorders: Epigenetic Programming in Gene‐Environment Interactions
Machado‐Vieira, R., Ibrahim, L., & Zarate, Jr. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00203.x · Cited by 117
Huntingtin in health and disease
Young, A. B. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17742 · Cited by 118
Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease
DeMarch, Z., Giampà, C., Patassini, S., Bernardi, G., & Fusco, F. R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.02.010 · Cited by 135
“Inhibition of cAMP response element (CRE)-mediated gene transcription has been hypothesized to contribute to HD pathology (Jiang et al., 2003, Kazantsev et al., 1999, Nucifora et al., 2001, Steffan et al., 2000, 2001).”
BackgroundBrain site-specific proteome changes in aging-related dementia
Manavalan, A., Mishra, M., Feng, L., Sze, S. K., Akatsu, H., & Heese, K. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.76 · Cited by 117
Tuning acetylation levels with HAT activators: Therapeutic strategy in neurodegenerative diseases
Selvi, B. R., Cassel, J., Kundu, T. K., & Boutillier, A. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.08.012 · Cited by 130
“SAHA, trichostatin A, and sodium butyrate have been shown to ameliorate disease progression in HD rodent models [103,134,135], and spinal and bulbar muscular atrophy, another polyQ disease [136].”
BackgroundImplications of Diet and The Gut Microbiome in Neuroinflammatory and Neurodegenerative Diseases
Hirschberg, S., Gisevius, B., Duscha, A., & Haghikia, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123109 · Cited by 117
“In Huntington ́s disease (HD), the polyglutamine-containing domain of the abnormal huntingtin protein was able to bind to HAT domains, therefore influencing the acetyltransferase activity [116].”
BackgroundTsunemi, T., & La Spada, A. R. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.10.004 · Cited by 117
The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease.
Janknecht, R. (2002) · PubMed · doi:10.14670/hh-17.657 · Cited by 144
Qiu, Z., Norflus, F., Singh, B., Swindell, M. K., Buzescu, R., Bejarano, M., Chopra, R., Zucker, B., Benn, C. L., DiRocco, D. P., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511648200 · Cited by 117
Targeting Histone Deacetylases as a Multifaceted Approach to Treat the Diverse Outcomes of Stroke
Langley, B., Brochier, C., & Rivieccio, M. A. (2009) · Stroke · doi:10.1161/strokeaha.108.540229 · Cited by 115
Mutant huntingtin represses CBP, but not p300, by binding and protein degradation
Cong, S., Pepers, B. A., Evert, B. O., Rubinsztein, D. C., Roos, R. A. C., van Ommen, G. B., & Dorsman, J. C. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.05.003 · Cited by 127
Vitalis, A., & Pappu, R. V. (2011) · Biophysical Chemistry · doi:10.1016/j.bpc.2011.04.006 · Cited by 114
“Products of proteolysis are rich in unprocessed polyglutamine regions [22, 23], which are prone to aggregation [6, 24-30] as well as recruitment and sequestration [6, 31, 32] of polyglutamine-rich regions from other proteins, specifically transcription factors [33-46].”
BackgroundKatsuno, M., Adachi, H., Minamiyama, M., Waza, M., Tokui, K., Banno, H., Suzuki, K., Onoda, Y., Tanaka, F., Doyu, M., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3032-06.2006 · Cited by 115
“In a fly model of HD, the HDAC inhibitors, sodium butyrate and suberoylanilide hydroxamic acid, increased histone acetylation, leading to the mitigation of neurodegeneration (Steffan et al., 2001).”
BackgroundOrso, G., Martinuzzi, A., Rossetto, M. G., Sartori, E., Feany, M., & Daga, A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24694 · Cited by 118
“(A) Images of NMJ immunocytochemistry using an anti-HRP antibody (red; middle panels), a neuronal maker of the presynaptic arbor, and an anti–acetylated α-tubulin antibody (AcTub, green; left panels), present only in stable microtubules (33), demonstrate that nervous system expression of Dspastin K467R induced accumul…”
Resultblue cheese Mutations Define a Novel, Conserved Gene Involved in Progressive Neural Degeneration
Finley, K. D., Edeen, P. T., Cumming, R. C., Mardahl-Dumesnil, M. D., Taylor, B. J., Rodriguez, M. H., Hwang, C. E., Benedetti, M., & McKeown, M. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01254.2003 · Cited by 113
“…have allowed genetic screens to identify modifiers of degenerative phenotypes (enhancers or suppressors) that would be difficult to characterize in other systems (Warrick et al., 1999; Fernandez-Funez et al., 2000; Kazemi-Esfarjani and Benzer, 2000; Steffan et al., 2001; Kazantsev et al., 2002).”
BackgroundMouse and fly models of neurodegeneration
Zoghbi, H. Y., & Botas, J. (2002) · Trends in Genetics · doi:10.1016/s0168-9525(02)02729-4 · Cited by 120
Storkebaum, E., Leitão-Gonçalves, R., Godenschwege, T. A., Nangle, L. A., Mejia, M., Bosmans, I., Ooms, T., Jacobs, A., Dijck, P. V., Yang, X., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905339106 · Cited by 121
“Our Drosophila DI-CMTC model will also be useful to screen drug libraries to identify potential therapeutic compounds, as reported before for Drosophila models of other neurodegenerative disorders (24, 25).”
MethodBobrowska, A., Paganetti, P., Matthias, P., & Bates, G. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020696 · Cited by 112
“Studies on HDAC inhibition have shown promising results in fly, worm and mouse models of HD [11,12,13,14].”
BackgroundHuntington and its Role in Neuronal Degeneration
Li, S.-H., & Li, X.-J. (2004) · The Neuroscientist · doi:10.1177/1073858404266777 · Cited by 111
Combinatorial chromatin modifications and memory storage: A code for memory?: Figure 1.
Wood, M. A., Hawk, J. D., & Abel, T. (2006) · Learning & Memory · doi:10.1101/lm.278206 · Cited by 111
“…histone modifications has also become central to other areas of neuroscience, including research in epilepsy (Huang et al. 2002; Tsankova et al. 2004), drug addiction (Kumar et al. 2005; Levine et al. 2005), depression (Tsankova et al. 2006), and neurodegenerative diseases (Steffan et al. 2001).”
BackgroundQi, M., Tagawa, K., Enokido, Y., Yoshimura, N., Wada, Y.-I., Watase, K., Ishiura, S., Kanazawa, I., Botas, J., Saitoe, M., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1553 · Cited by 112
Munoz-Sanjuan, I., & Bates, G. P. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45364 · Cited by 109
Multiple pathways contribute to the pathogenesis of Huntington disease.
Li, S., & Li, X. (2006) · Molecular Neurodegeneration · doi:10.1186/1750-1326-1-19 · Cited by 122
Acetyltransferases (HATs) as Targets for Neurological Therapeutics
Schneider‐Anthony, A., Chatterjee, S., Bousiges, O., Selvi, B. R., Swaminathan, A., Cassel, R., Blanc, F., Kundu, T. K., & Boutillier, A. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0204-7 · Cited by 134
“HDACi-based therapeutic strategies were first applied to models of polyglutamine (polyQ) diseases, such as Huntington’s [8, 9] and Kennedy’s [10], and then subsequently revealed to be successful to some extent in several other animal models of neurodegenerative disease [5, 6, 11, 12].”
BackgroundMethodInfluentialFischer, A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.01.038 · Cited by 123
“Moreover CBP has been implicated with the pathogenesis of Huntington’s disease, where it was found that mutant huntingtin protein interacts with CBP and thereby deregulates gene-expression (Steffan et al., 2000) (Steffan et al., 2001).”
BackgroundEpigenetic memory: The Lamarckian brain
Fischer, A. (2014) · The EMBO Journal · doi:10.1002/embj.201387637 · Cited by 107
“…3 A also appears to play a role in the pathogenesis of Huntington ’ s disease (HD), where it was found that mutant Huntingtin protein interacts with CBP/KAT 3 A and thereby deregulates gene expression (Steffan et al , 2000 ; Steffan et al , 2001 ; Cong et al , 2005 ; Jiang et al , 2006 ).”
Neuroprotective Effects of Phenylbutyrate Against MPTP Neurotoxicity
Gárdián, G., Yang, L., Cléren, C., Calingasan, N. Y., Klivènyi, P., & Beal, M. F. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:3:235 · Cited by 111
“Administration of HDAC inhibitors is neuroprotective in vitro, in Drosophila models and in transgenic mouse models of Huntington’s disease (HD) NeuroMolecular Medicine Volume 5, 2004 (McCampbell et al., 2001; Steffan et al., 2001; Ferrante et al., 2003; Hockly et al., 2003).”
Identification of Neural Outgrowth Genes using Genome-Wide RNAi
Sepp, K. J., Hong, P., Lizarraga, S. B., Liu, J. S., Mejia, L. A., Walsh, C. A., & Perrimon, N. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000111 · Cited by 106
“For example, analyses of Drosophila Huntington’s Disease (HD) models have been the first to discover the role of Histone Deacetylases in suppressing HD phenotypes [63], to show disruption of axon trafficking in HD models [42,64], and to demonstrate that genetic reduction of SUMOylation reduces neurodegeneration of the…”
BackgroundGhosh, S., & Feany, M. B. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh214 · Cited by 106
Fontán‐Lozano, Á., Romero‐Granados, R., Troncoso, J., Múnera, A., Delgado-Garcia, J. M., & Carrión, Á. M. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.06.009 · Cited by 122
“…is also a fundamental molecular mechanism for the transcriptional regulation related with neurodevelopmental and neurodegenerative disorders, epilepsy, and drug addiction (Steffan et al., 2001; Shahbazian and Zoghbi, 2002; Hockly et al., 2003; Levenson and Sweatt, 2005; Levine et al., 2005).”
BackgroundHuntington Disease and the Huntingtin Protein
Zheng, Z., & Diamond, M. I. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00010-2 · Cited by 142
Luthi-Carter, R., Apostol, B. L., Dunah, A. W., DeJohn, M. M., Farrell, L. A., Bates, G. P., Young, A. B., Standaert, D. G., Thompson, L. M., & Cha, J.-H. J. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.08.024 · Cited by 104
“Other investigators have shown that huntingtin can associate with tyrosine kinases (i.e., the phosphorylated form of the epidermal growth factor receptor) (Liu et al., 1997) and kinase interacting proteins (Grb2, RasGAP, shc and SH3GL3) (Liu et al., 1997; Sittler et al., 1998 ).”
BackgroundSelf-citationSchilling, G., Savonenko, A. V., Klevytska, A., Morton, J. L., Tucker, S. M., Poirier, M., Gale, A., Chan, N., Gonzales, V., Slunt, H. H., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh175 · Cited by 104
“However, in work focusing on the CBP pathway, several studies have demonstrated that restoring this pathway by augmenting CBP function through transgene expression (24) or by inhibiting histone deacetylases pharmacologically (CBP is a histone acetylase) ( 50 ,63) diminishes the toxicity of mutant htt.”
Drosophila Models of Parkinson's Disease
Whitworth, A. J. (2011) · Advances in genetics · doi:10.1016/b978-0-12-380860-8.00001-x · Cited by 123
“These findings are particularly compelling since other HDAC inhibitors have been shown to ameliorate expanded polyglutamine-induced toxicity (Steffan et al., 2001).”
BackgroundA fruitful endeavor: Modeling ALS in the fruit fly
Casci, I., & Pandey, U. B. (2015) · Brain Research · doi:10.1016/j.brainres.2014.09.064 · Cited by 103
“Many key discoveries that have helped in advancing the neurodegenerative disease field have been made using flies as a model system including, but not limited to, the identification of candidate genes as causes and therapies of disease (Fernandez-Funez et al., 2000;Steffan et al., 2001;Warrick et al., 1999), in vivo e…”
BackgroundPARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington’s Disease
Cardinale, A., Paldino, E., Giampà, C., Bernardi, G., & Fusco, F. R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134482 · Cited by 103
“Inhibition of CREB-mediated transcription is involved in the neurodegeneration occurring in HD [42] and a decreased transcription of CREB-regulated genes is observed in HD transgenic animals [43].”
BackgroundWacker, J. L., Huang, S.-Y., Steele, A. D., Aron, R., Lotz, G. P., Nguyen, Q., Giorgini, F., Roberson, E. D., Lindquist, S., Masliah, E., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.2250-09.2009 · Cited by 103
“Interestingly, as mutant htt inhibits the acetyltransferase activity of CREB-binding protein (CBP) (Steffan et al., 2000; Steffan et al., 2001), which itself controls c-Fos expression (Yuan et al., 2009), it is possible that aberrant protein interactions between mutant htt and CBP, and suppression…”
Ying, M., Xu, R., Wu, X., Zhu, H., Zhuang, Y., Han, M., & Xu, T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511677200 · Cited by 102
Jin, Y. N., Yu, Y. V., Gundemir, S., Jo, C., Cui, M., Tieu, K., & Johnson, G. V. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057932 · Cited by 102
“CBP/p300 has been shown to interact with mHtt, which results in inhibition of their acetyltransferase activity [68,69].”
BackgroundOssato, G., Digman, M. A., Aiken, C. T., Lukácsovich, T., Marsh, J., & Gratton, E. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.02.058 · Cited by 112
Self-citationHu, Y., Chopra, V., Chopra, R., Locascio, J. J., Liao, Z., Ding, H., Zheng, B., Matson, W. R., Ferrante, R. J., Rosas, H. D., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104409108 · Cited by 102
“In a Drosophila model, HDAC inhibitors suppress neurodegeneration (34).”
MethodAchour, M., Le Gras, S., Keime, C., Parmentier, F., Lejeune, F.-X., Boutillier, A.-L., Neri, C., Davidson, I., & Merienne, K. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv099 · Cited by 102
The genetics of cognitive epigenetics
Kleefstra, T., Schenck, A., Kramer, J. M., & van Bokhoven, H. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.12.025 · Cited by 125
Todd, P. K., Oh, S. Y., Krans, A., Pandey, U. B., Di Prospero, N. A., Min, K.-T., Taylor, J. P., & Paulson, H. L. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001240 · Cited by 101
“At doses known to suppress polyglutamine-induced neurodegeneration [31], the drug had no effect on the normal eye phenotype in eGFP expressing flies (Figure S1A).”
BackgroundSontag, E. M., Lotz, G. P., Agrawal, N., Tran, A., Aron, R., Yang, G., Necula, M., Lau, A., Finkbeiner, S., Glabe, C., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0895-12.2012 · Cited by 101
Self-citationYildirim, F., Gertz, K. R., Kronenberg, G., Harms, C., Fink, K., Meisel, A., & Endres, M. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.11.031 · Cited by 106
“pathogenesis of neurodegeneration and recent studies have demonstrated HDAC inhibitors to be protective in animal models of Huntington's disease (Steffan et al., 2001; McCampbell et al., 2001; Ferrante et al., 2003; Hockly et al., 2003), amyotrophic lateral sclerosis (Ryu et al.”
Result
Metadata
- Authors
- Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., Kurokawa, R., Housman, D. E., Jackson, G. R., Marsh, J. L., & Thompson, L. M.
- Affiliations
- University of California, Irvine (US)
- National Institutes of Health (US)
- Massachusetts Institute of Technology (US)
- University of California San Diego (US)
- University of California, Los Angeles (US)
- Corresponding author
- Thompson, Leslie M.
- ORCID
- Venue
- Nature
- Published
- 2001-10
- Volume
- 413
- Issue
- 6857
- Pages
- 739-743
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1643390591
- Cited by
- 1,228
- References
- 28
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 35 · 2020: 35 · 2019: 30 · 2018: 37 · 2017: 34 · 2016: 40 · 2015: 46 · 2014: 63 · 2013: 65 · 2012: 55
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Hereditary Disease Foundation
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- histone deacetylase inhibitors, polyglutamine expansion, Huntington's disease, neurodegeneration, huntingtin exon 1, CREB-binding protein, P300, PCAF, histone acetylation, histone deacetylase, Drosophila model, transcriptional dysregulation
- MeSH terms
- Huntingtin Protein, Acetylation, Acetyltransferases, Animals, Disease Models, Animal, Drosophila, Enzyme Inhibitors, Gene Expression Regulation, Glutamine, Glutathione Transferase, Histone Deacetylases, Histones, Huntington Disease, Nerve Degeneration, Nerve Tissue Proteins, Nuclear Proteins, Peptides, Repressor Proteins, Trans-Activators, PC12 Cells, Protein Structure, Tertiary, Neurodegenerative Diseases, Repetitive Sequences, Amino Acid, Saccharomyces cerevisiae Proteins, Drosophila Proteins, Animals, Genetically Modified, E1A-Associated p300 Protein, CREB-Binding Protein, Rats, Histone Acetyltransferases, Sin3 Histone Deacetylase and Corepressor Complex, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.